Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer. (2nd January 2023)

• Record Type: Journal Article
• Authors: Singh, Nilanchali; Jayraj, Aarthi S; Sarkar, Avir; Mohan, Trishala; Shukla, Amlin; Ghatage, Prafull
• Is Part Of: Expert opinion on pharmacotherapy. Volume 24:Number 1(2023)
• Page Start: 49
• Page End: 64
• Publication Date: 2023-01-02
• Subjects: Recurrent epithelial ovarian cancer -- chemotherapy -- secondary cytoreductive surgery -- targeted therapy -- bevacizumab -- PARP inhibitors -- immunotherapy; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2022.2112030
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Almost 80% of epithelial ovarian cancer present in advanced stage at diagnosis and despite excellent response to surgery and chemotherapy, more than 70% cancers recur. Subsequent therapies become decreasingly effective in controlling the disease, with each successful therapy being effective for a shorter duration. As a result, there is a need for novel therapeutic strategies to effectively treat recurrence. Areas covered: In this extensive literature review of high-quality articles, we have focused on surveillance strategy to detect recurrence early, classification of recurrence based on timeline, role of surgery, chemotherapy, and targeted agents such as anti-angiogenetic drugs, PARP inhibitors, and immune checkpoint inhibitors in platinum-sensitive and platinum-resistant disease, respectively. Expert opinion: Recurrent ovarian cancers (ROC) are represented by a heterogenous group of patient population in terms of platinum-free interval (PFI), histology, molecular characteristics and immune recognition. In today's era of precision medicine, chemotherapy should be combined with appropriate targeted agent in a multipronged approach to prolong survival and provide better quality of life outcomes by minimizing side effects.